CAPRICOR THERAPEUTICS, INC. (NASDAQ:CAPR) Files An 8-K Other Events
Item 8.01 Other Events.
On May 12, 2017, Capricor Therapeutics, Inc. (the Company)
announced that a pre-specified administrative interim analysis
performed on six-month follow-up data from its ALLSTAR Trial has
demonstrated a low probability (futility) of achieving a
statistically-significant difference in the 12 month primary
efficacy endpoint of percent change from baseline infarct size as
a percentage of left ventricular mass, measured by cardiac
magnetic resonance imaging (MRI). The ALLSTAR Trial is an ongoing
randomized, double-blind, placebo-controlled, 142-patient Phase
II clinical trial of CAP-1002 in adults who have experienced a
large heart attack with residual cardiac dysfunction. Capricor
will continue to perform analyses of the cumulative ALLSTAR data
to better understand the basis for this outcome.
In response to the ALLSTAR results, the Company plans to reduce
the scope of its operations, including the size of its workforce,
in order to focus its financial resources primarily on its
Duchenne muscular dystrophy (DMD) program.
Item 9.01. Financial Statements and Exhibits.
| (d) | Exhibits. |
| ExhibitNumber | Description |
| 99.1 |
Press Release issued by Capricor Therapeutics, Inc. on May 12, 2017, providing update on ALLSTAR trial. |
About CAPRICOR THERAPEUTICS, INC. (NASDAQ:CAPR)
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles. CAPRICOR THERAPEUTICS, INC. (NASDAQ:CAPR) Recent Trading Information
CAPRICOR THERAPEUTICS, INC. (NASDAQ:CAPR) closed its last trading session up +0.08 at 3.05 with 64,917 shares trading hands.
